|

Hormone Replacement Trial Against ALzheimers' Disease

RECRUITINGN/ASponsored by University Hospital, Ghent
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Ghent
Started2018-04-17
Est. completion2027-12-31
Eligibility
Age40 Years – 65 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04312399

Summary

The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.

Eligibility

Age: 40 Years – 65 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* postmenopausal women
* 40 - 65 years

Exclusion Criteria:

* Longer than 10 years in menopause
* thyroid dysfunction
* hypertension
* medical history of psychiatric comorbidity
* Alcohol and/or drug abuse
* medical history of neurologic symptoms with cognitive symptoms

Conditions3

Alzheimer DiseaseAlzheimer's DiseasePostmenopausal Symptoms

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.